Glucagon-like peptide-1 receptor agonists vs alternative therapies are not associated with increased risk for suicide and may lower risk.

GLP-1 receptor agonists may help mitigate progression of at least some obesity-related cancers, according to retrospective ...

New findings to be presented at ASCO 2026 suggest GLP-1 medicines may help reduce cancer progression, although experts say ...

No difference in mortality risk seen for GLP-1 RA and SGLT2i users; significantly lower risk seen for GLP-1 RA vs DPP4i users. HealthDay News — For older patients with cancer and type 2 diabetes (T2D) ...

"Although there was a signal of lower incidence of dementia with GLP-1 RAs than with DPP4is among adults younger than 75 years, the causal relationship remains unclear." HealthDay News — For older ...

The glucagon-like peptides (GLP-1 and GLP-2) are processed from the proglucagon polypeptide and secreted in equimolar amounts but have opposite effects on chylomicron (CM) production, with GLP-1 ...

About The Study: In older patients with cancer and type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1RA) use was associated with lower all-cause mortality compared with dipeptidyl ...

GLP-1 RA therapy linked to significantly lower risk for epilepsy compared with DPP4-i use among adults with T2DM. (HealthDay News) — For adults with type 2 diabetes mellitus (T2DM), glucagon-like ...

Among patients with type 2 diabetes and select cancers, GLP1-RA use is associated with better survival chances. For patients with cancer and type 2 diabetes (T2DM), use of glucagon-like peptide-1 ...

About The Study: In this nationwide cohort study of patients with diabetes and prior major adverse limb events, treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) was associated with ...